AGS 004

Drug Profile

AGS 004

Alternative Names: AGS-004; AGS-004-001; Arcelis

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Argos Therapeutics Inc; Kirin Holdings Company
  • Developer Argos Therapeutics Inc
  • Class Antivirals; Dendritic cell vaccines; Viral vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 26 Jul 2017 Immunogenicity and adverse events data from a phase I/II trial in HIV-1 infections released by Argos Therapeutics
  • 26 Jun 2017 Phase-II development in HIV-infections is ongoing in USA and Canada
  • 08 Mar 2016 The University of North Carolina at Chapel Hill and the National Institute of Allergy and Infectious Diseases plan the pilot phase I VORVAX trial for HIV-1 infections in USA (PO) (NCT02707900)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top